How much cash will Forian (FORA) shareholders receive per share in the merger?

Each issued and outstanding Forian common share will be converted into the right to receive $2.17 in cash per share , without interest and subject to required tax withholding. Certain shares held by Forian, its subsidiaries and buyer-affiliated entities will be cancelled without consideration.

Forian (FORA) holders to receive $2.17 per share in all-cash buyout

Q: How many Forian (FORA) shares were outstanding for ownership calculations in this filing?

Ownership percentages in the filing are calculated using 31,208,751 Forian common shares outstanding as of March 25, 2026. This outstanding share count comes from Forian’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, referenced throughout the amendment.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

Forian Inc. has entered into a definitive merger agreement under which a consortium-led vehicle, 2025 Acquisition Company, LLC, will acquire Forian through a tender offer followed by a merger. Each outstanding common share will be converted into the right to receive $2.17 in cash, without interest and subject to tax withholding.

The filing details an amended consortium agreement, adds new consortium members, and describes an equity commitment letter under which a Wygod/Bushnell family trust has committed up to $5.5 million of equity funding to support closing payments. Completion of the offer and subsequent merger is subject to customary conditions, including a minimum tender of more than 50% of outstanding shares and the absence of a continuing Company Material Adverse Effect.

Positive

Definitive cash exit at $2.17 per share: The consortium agreement and merger plan provide shareholders with a clear all-cash consideration of $2.17 per common share, subject to completion of the tender offer and merger conditions.
Equity funding support for the transaction: A Wygod/Bushnell family trust has committed up to $5.5 million of equity capital to fund closing payments under the merger agreement, helping to support execution of the agreed cash consideration.

Negative

None.

Insights

Forian agrees to a cash buyout at $2.17 per share via tender offer and merger.

Forian Inc. is targeted by a consortium that will acquire all outstanding common shares for $2.17 in cash per share. The structure uses a tender offer by a special purpose vehicle, followed by a short-form merger under Maryland law to take the company private once conditions are met.

The amendment clarifies that the consortium agreement remains in force, adds several new shareholders to the group, and restricts share transfers before closing, except to specified transferees who agree to be bound. A Wygod/Bushnell family trust has provided an equity commitment of up to $5.5 million to fund closing payments, available solely to complete the transaction.

Closing depends on more than 50% of shares being tendered, the accuracy of key representations, performance of covenants, no continuing Company Material Adverse Effect, and no blocking court order. Subsequent company filings, including the Schedule TO, Schedule 13E-3 and Schedule 14D-9 referenced here, will provide additional detail on timing, board recommendations and any appraisal rights process.

Key Figures

Cash consideration per share: $2.17 per share Equity commitment: $5,500,000 Shares outstanding baseline: 31,208,751 shares +4 more

7 metrics

Cash consideration per share $2.17 per share Merger consideration for each issued and outstanding Forian common share

Equity commitment $5,500,000 Maximum equity funding committed by Wygod/Bushnell family trust Sponsor

Shares outstanding baseline 31,208,751 shares Forian common shares outstanding as of March 25, 2026, per Form 10-K

Consortium aggregate beneficial ownership 20,689,142 shares Shares beneficially owned in aggregate by consortium members, with ownership disclaimed beyond individual reports

Vuolo reported stake 4,015,795 shares (12.9%) Aggregate amount beneficially owned by Anthony Vuolo, including trust-held shares, based on 31,208,751 shares outstanding

Max C. Wygod reported stake 3,859,402 shares (12.4%) Aggregate amount beneficially owned by Max C. Wygod, based on 31,208,751 shares outstanding

Adam H. Dublin reported stake 2,505,533 shares (8%) Aggregate amount beneficially owned by Adam H. Dublin, based on 31,208,751 shares outstanding

Key Terms

Consortium Agreement, Merger Agreement, Equity Commitment Letter, tender offer statement on Schedule TO, +2 more

6 terms

Consortium Agreement financial

"the Consortium entered into the Amendment No. 1 (the "Consortium Agreement Amendment") to the Consortium Agreement"

Merger Agreement financial

"entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement")"

A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.

Equity Commitment Letter financial

"provided an equity commitment letter dated April 2, 2026 (the "Equity Commitment Letter")"

A written promise from an investor or group to provide a specified amount of capital for a deal, such as an acquisition or a new financing round. It matters to investors because it shows how likely a transaction is to close and how much fresh money will be available, similar to a down-payment commitment when buying a house: the stronger the promise, the less risk that the deal will fall apart or that existing shareholders will face unexpected dilution.

tender offer statement on Schedule TO regulatory

"the preparation and filing of a tender offer statement on Schedule TO and a transaction statement on Schedule 13E-3"

A tender offer statement on Schedule TO is a formal regulatory filing that lays out the full terms, timeline, and conditions of a public offer to buy shares from existing shareholders. Think of it as a detailed invitation that explains who is buying, how much they’ll pay, how long the offer runs, and any rules or financing behind it. Investors use it to judge the fairness, likelihood and timing of a buyout and its likely effect on share value and control.

Schedule 13E-3 regulatory

"the preparation and filing of a tender offer statement on Schedule TO and a transaction statement on Schedule 13E-3 by Parent, Merger Sub and the Company"

Schedule 13E-3 is a formal SEC filing that companies or their insiders must submit when proposing a buyout that would take a public company private or is otherwise a management-led purchase. It lays out who is behind the deal, the money and terms involved, any potential conflicts of interest, and independent fairness analysis so shareholders can assess whether the offer is fair—like the rulebook and disclosure packet you’d get before agreeing to sell your home.

Section 13(d)(3) of the Act regulatory

"may be deemed to have formed a "group" for purposes of Section 13(d)(3) of the Act"

04/06/2026 - 09:37 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 2)

Forian Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

34630N106

(CUSIP Number)

Creighton Condon
599 Lexington Ave.,
New York, NY, 10022
(212) 848-7628

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

04/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.001 par value per share

(b)

Name of Issuer:

Forian Inc.

(c)

Address of Issuer's Principal Executive Offices:

41 University Drive, Suite 400, Newtown, PENNSYLVANIA , 18940.

Item 1 Comment:

This Amendment No. 2 to Schedule 13D ("Amendment No. 2") relates to shares of Common Stock, par value $0.001 per share ("Shares") of Forian Inc., a Delaware corporation (the "Issuer"). This Amendment No. 2 is being jointly filed on behalf of the following persons (collectively, the "Reporting Persons"): (i) 2025 Acquisition Company, LLC (the "SPV"), a Delaware limited liability company, (ii) Max. C. Wygod, an individual, (iii) Emily Bushnell, an individual, (iv) the ADMINISTRATIVE TRUST U/ WYGOD FAMILY RV (the "Administrative Trust"), (v) the MAX WYGOD & EMILY W BUSHNELL CO-TTEE WYGOD FAMILY REV LT U/T/A (vi) Anthony Vuolo, an individual, (vii) the MAX WYGOD FAMILY DYNASTY TRUST, (viii) ORACLE PARTNERS, L.P., a Delaware limited partnership ("Partners"), (ix) ORACLE INSTITUTIONAL PARTNERS, L.P., a Delaware limited partnership ("Institutional Partners"), (x) ORACLE INVESTMENT MANAGEMENT, INC. EMPLOYEES' RETIREMENT PLAN, a employee benefit plan organized in Connecticut (the "Retirement Plan"), (xi) the FEINBERG FAMILY FOUNDATION, a foundation organized in Connecticut (the "Foundation"), (xii) ORACLE ASSOCIATES, LLC, a Delaware limited liability company ("Oracle Associates"), (xiii) ORACLE INVESTMENT MANAGEMENT, INC., a Delaware corporation(the "Investment Manager"), (xiv) Larry N. Feinberg, an individual, (xv) the FEINBERG FAMILY TRUST, a Connecticut Trust, (xvi) Adam Usdan, solely as trustee of the FEINBERG FAMILY TRUST, (xvii) Adam H. Dublin, an individual, (xviii) the ADAM H. DUBLIN 2019 FAMILY TRUST, (xix) Phyllis Dublin, solely as co-trustee of the ADAM H. DUBLIN 2019 FAMILY TRUST, (xx) Edward Francis Spaniel, Jr., an individual and co-trustee of the ADAM H. DUBLIN 2019 FAMILY TRUST, (xxi) Carl Berg, an individual on behalf of Alexander Ryan Berg, Adam Charles Berg, Eric William Berg, and Emma RoseBerg, (xxii) MARBLE LANE PARTNERS I, LLC, (xxiii) Michael Sawyer, an individual, (xxiv) NELL AND JANE CAMERON 2006 TRUST, (xxv) Keri Cameron, solely on behalf of the NELL AND JANE CAMERON 2006 TRUST, (xxvi) Shahir Kassam-Adams, an individual, (xxvii) 360 Ventures, LLC, a Virginia limited liability company, (xxviii) Charles Mele, an individual, (xxix) Michael and Sharon Glick, as individuals holding shares in joint tenancy, (xxx) BRAVO MERGER SUB, INC., a Maryland corporation ("Merger Sub"), (xxxi) the THOMAS J. COLEMAN REVOCABLE TRUST, a New York Trust, (xxxii) Milk Town Partners LLC, a Connecticut partnership, (xxxiii) Todd Dublin, an individual, and (xxxiv) Peter Dublin, an individual, and amends the Statement on Schedule 13D filed by the Reporting Persons on August 25, 2025 ("Initial Schedule 13D").

Item 2.

Identity and Background

(a)

Item 2(a) of the Initial Schedule 13D is hereby amended and supplemented by adding the following text: Bravo Merger Sub, Inc., a Maryland corporation, Thomas J. Coleman Revocable Trust, a New York Trust, Milk Town Partners LLC, a Connecticut partnership, Todd Dublin, an individual, and Peter Dublin, an individual.

(b)

Item 2(b) of the Initial Schedule 13D is hereby amended and supplemented by adding the following text: Bravo Merger Sub, Inc. The principal address for the corporation is Max C. Wygod, c/o A&O Shearman, ATTN: Chris Glenn, 599 Lexington Avenue, New York, NY 10022. Thomas J. Coleman Revocable Trust. The principal address for the trust is c/o Kensico Capital Management 55 Railroad Avenue, 2nd Fl Greenwich, CT 06830. Milk Town Partners LLC. The principal address for the company is c/o Kensico Capital Management 55 Railroad Avenue, 2nd Fl Greenwich, CT 06830. Todd Dublin. Mr. Todd Dublin's address is 1304 South Halliburton Street, Kirksville, MO 63501. Peter Dublin. Mr. Peter Dublin's address is 224 Franklin Avenue, River Forest, IL 60305

(c)

Item 2(c) of the Initial Schedule 13D is hereby amended and supplemented by adding the following text: Item 2(b) of this Amendment No. 2 is incorporated herein by reference.

(d)

None

(e)

None

(f)

United States

Item 4.

Purpose of Transaction

The disclosure in Item 4 of the Existing Schedule 13D is hereby amended and supplemented by adding the following at the end thereof: Amendment No. 1 to the Consortium Agreement On April 2, 2026, the Consortium entered into the Amendment No. 1 (the "Consortium Agreement Amendment") to the Consortium Agreement (as defined in the Initial 13D), which, among other things, (i) clarifies that the Consortium Agreement remains in full force and effect, notwithstanding any terms therein to the contrary, (ii) provides that the Consortium Agreement will terminate upon the closing of the Merger (as defined below) or a valid termination of the Merger Agreement (as defined below), (iii) imposes certain restrictions to the transfer of Shares prior to such termination (subject to limited permitted transfers to specified transferees who agree to be bound), and (iv) requires each Consortium Member to contribute its Shares to Parent prior to the commencement of the Offer. Merger Agreement Subsequently, on April 2, 2026, the SPV, Bravo Merger Sub, Inc., a Maryland corporation and wholly-owned subsidiary of the SPV ("Merger Sub") and Forian entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement"). Pursuant to the Merger Agreement, among other things, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into the Company (the "Merger" and, together with the other transactions contemplated by the Merger Agreement, collectively, the "Transactions"), and the separate corporate existence of Merger Sub will thereupon cease, and the Company will continue as the surviving corporation and a wholly owned subsidiary of Parent. The Merger will be governed by Section 3-106.1 of the MGCL and will be effected by Merger Sub and Forian without a stockholder vote as soon as practicable following the consummation of the Offer, pursuant to the MGCL. At the effective time of the Merger (the "Effective Time"), each Share issued and outstanding immediately prior to the Effective Time (other than Shares (i) held by Forian and its subsidiaries, (ii) owned by the Buyer Parties, or (iii) owned by any direct or indirect wholly owned subsidiary of the Buyer Parties as of immediately prior to the Effective Time, which will be automatically cancelled and extinguished without any conversion thereof or consideration paid therefor), subject to any appraisal rights in accordance with Section 3-202 of the MGCL, will be converted into the right to receive $2.17 in cash per Share, without interest, and subject to deduction for any required tax withholding. Each of the Company, Parent and Merger Sub has made customary representations, warranties and covenants in the Merger Agreement, including relating to (i) the conduct of the Company's business during the interim period, (ii) the efforts of each party to cause the Transactions to be completed and (iii) the preparation and filing of a tender offer statement on Schedule TO and a transaction statement on Schedule 13E-3 by Parent, Merger Sub and the Company and a Schedule 14D-9 by the Company in connection with the Transactions. Completion of the Merger is subject to certain closing conditions, including, but not limited to, (i) that the number of Shares validly tendered and not validly withdrawn, together with the number of Shares then owned beneficially by Parent and Merger Sub (together with their wholly owned subsidiaries), equals at least one share more than fifty percent (50%) of all Shares outstanding as of the consummation of the Offer, (ii) the truth and accuracy of certain representations and warranties of Forian as set forth in the Merger Agreement as of the date of the Merger Agreement and as of the expiration date of the Offer (the "Expiration Date") as if made on and as of each such date (as may be subject to materiality, de minimis or other qualifiers), (iii) Forian having performed and complied in all material respects with the covenants, obligations and conditions of the Merger Agreement required to be performed and complied with by Forian at or prior to the Expiration Date, (iv) the non-occurrence of a Company Material Adverse Effect (as defined in the Merger Agreement) on or after the date of the Merger Agreement that is continuing, (v) the non-termination of the Merger Agreement, and (vii) the non-issuance of any judgment, temporary restraining order, preliminary or permanent injunction, or other order from any governmental body of competent jurisdiction preventing the consummation of the Offer or the Merger. Equity Commitment Letter In connection with the Transactions, one of the members of the Consortium, Max Wygod & Emily W Bushnell Co-TTEE Wygod Family Rev LT U/T/A (the "Sponsor"), provided an equity commitment letter dated April 2, 2026 (the "Equity Commitment Letter"), pursuant to which it committed to provide Parent, on the terms and subject to the conditions set forth therein, an aggregate equity commitment of up to $5,500,000 (or such lesser amount required for Merger Sub to fund the purchase, directly or indirectly, of the securities of Parent) to fund the Closing Payments (as defined in the Equity Commitment Letter) under the Merger Agreement (the "Commitment"). The Commitment is available solely to consummate the Transactions and is fundable at or prior to the consummation of the Merger, subject to, among other things, the execution of the Merger Agreement, and the satisfaction or waiver of the conditions of the Merger Agreement. The Equity Commitment Letter also permits allocation of all or a portion of the Commitment to affiliated entities, includes customary non-recourse provisions in favor of non-parties, provides that the Company is an express third-party beneficiary solely entitled to seek specific performance to cause funding of the Commitment, and terminates upon the earliest of the consummation of the Merger, valid termination of the Merger Agreement, or full funding of the Commitment. The foregoing descriptions of the Consortium Agreement Amendment, the Merger Agreement and the Equity Commitment Letter do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed herewith as Exhibits 99.18, 99.19, 99.20, respectively, and are incorporated herein by reference.

Item 5.

Interest in Securities of the Issuer

(a)

Item 5(a) of the Initial 13D is hereby amended and supplemented by adding the following text: The information set forth in rows 11 and 13 of the cover pages of this Amendment No. 2 is incorporated herein by reference. See rows (7) through (10) of the cover pages to this Amendment No. 2 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition. After obtaining consent from the Special Committee of the Board of Directors of the Company and duly executing the Consortium Agreement as of April 2, 2026, prior to the execution of the Merger Agreement, the following shareholders have been added to the Consortium (as defined in Item 4 of the Initial 13D): Thomas J. Coleman Revocable Trust, Milk Town Partners LLC, Todd Dublin and Peter Dublin (the "New Consortium Members"). All references to the Consortium in this Amendment No. 2 and any future amendments to the Initial 13D shall include these shareholders. Because of the arrangements in the Consortium Agreement (as defined in Item 4 of the Initial 13D), the members of the Consortium (as defined in Item 4 of the Initial 13D) may be deemed to have formed a "group" for purposes of Section 13(d)(3) of the Act. Neither the filing of this Schedule 13D nor any of its contents, however, shall be deemed to constitute an admission by the Reporting Persons that any of them is the beneficial owner of any of the 20,689,142 Shares beneficially owned in the aggregate by the Consortium Members, other than such Shares that each Reporting Person has reported as beneficially owned by the respective Reporting Person in this Amendment No. 2, for purposes of Section 13(d) of the Act or for any other purpose, and such beneficial ownership is expressly disclaimed.

(b)

Item 5(b) of the Initial 13D is hereby amended and supplemented by adding the following text: Except as set forth in this Amendment No. 2, none of the Reporting Persons beneficially owns, or has acquired or disposed of, any Shares during the last 60 days.

(d)

To the knowledge of the Reporting Persons, no person other than each of the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, Shares beneficially owned by such Reporting Persons.

(e)

Not applicable.

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of this Schedule 13D is hereby amended and supplemented by adding the following text: Item 4 references the Consortium Agreement Amendment, the Merger Agreement and the Equity Commitment Letter, the descriptions of each of which are incorporated herein by reference. Copies of the Consortium Agreement Amendment, the Merger Agreement and the Equity Commitment Letter are attached as 99.18, 99.19, 99.20, respectively to this Amendment No. 2, and are incorporated herein by reference.

Item 7.

Material to be Filed as Exhibits.

Item 7 of the Initial 13D is hereby amended and supplemented by the addition of the following Exhibits: Exhibit 99.4* - Power of Attorney for Adam H. Dublin, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.4 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.5* - Power of Attorney for Adam Usdan, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.5 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.6* - Power of Attorney for Anthony Vuolo, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.6 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.7* - Power of Attorney for Carl Berg, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.7 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.8* - Power of Attorney for Charles Mele, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.8 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.9* - Power of Attorney for Edward Francis Spaniel Jr., dated as of October 2, 2025 (incorporated by reference to Exhibit 99.9 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.10* - Power of Attorney for Keri Cameron, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.10 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.11* - Power of Attorney for Larry Feinberg, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.11 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.12* - Power of Attorney for Marble Lane Partners I, LLC, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.12 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.13* - Power of Attorney for Michael Glick, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.13 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.14* - Power of Attorney for Michael Sawyer, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.14 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.15* - Power of Attorney for Phyllis Dublin, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.15 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.16* - Power of Attorney for Adam Kassam-Adams, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.16 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.17* - Power of Attorney for Emily Bushnell, dated as of October 2, 2025 (incorporated by reference to Exhibit 99.17 to the Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on October 2, 2025). sec.gov/Archives/edgar/data/1829280/000094787125000884/xslSCHEDULE_13D_X01/primary_doc.xml Exhibit 99.18 - Amendment No. 1 to the Consortium Agreement, dated April 2, 2026, by and among Mr. Max Wygod and the Consortium Members Exhibit 99.19* - Agreement and Plan of Merger, dated April 2, 2026, by and among the SPV, Merger Sub and the Issuer (incorporated by reference to Exhibit 2.1 to the Issuer's Current Report on Form 8-K, filed April 3, 2026). Exhibit 99.20 - Equity Commitment Letter, dated April 2, 2026, by and between the SPV and the Sponsor. Exhibit 99.21* - Press Release, dated April 2, 2026 (incorporated by reference to Exhibit 99.1 to the Issuer's Current Report on Form 8-K filed, filed April 3, 2026). Exhibit 99.22 - Power of Attorney for Peter Dublin, dated April 2, 2026. Exhibit 99.23 - Power of Attorney for Todd Dublin, dated April 2, 2026. Exhibit 99.24 - Power of Attorney for Thomas J. Coleman, dated April 2, 2026. *Previously filed.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

2025 Acquisition Company, LLC

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod
Date:	04/06/2026

Bravo Merger Sub, Inc.

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod
Date:	04/06/2026

Max C. Wygod

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod
Date:	04/06/2026

Emily Bushnell

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Emily Bushnell
Date:	04/06/2026

ADMINISTRATIVE TRUST U/ WYGOD FAMILY RV

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod, Co-Trustee
Date:	04/06/2026

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Emily Bushnell, Co-Trustee
Date:	04/06/2026

Anthony Vuolo

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Anthony Vuolo
Date:	04/06/2026

MAX WYGOD & EMILY W BUSHNELL CO-TTEE

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod, Co-Trustee
Date:	04/06/2026

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Emily Bushnell, Co-Trustee
Date:	04/06/2026

MAX WYGOD FAMILY DYNASTY TRUST

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Anthony Vuolo, Trustee
Date:	04/06/2026

FEINBERG LARRY N

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg
Date:	04/06/2026

ORACLE PARTNERS, L.P.

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, Managing Member
Date:	04/06/2026

ORACLE INSTITUTIONAL PARTNERS, L.P.

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, Managing Member
Date:	04/06/2026

Todd Dublin

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Todd Dublin
Date:	04/06/2026

ORACLE INVESTMENT MANAGEMENT, INC. EMPLOYEES' RETIREMENT PLAN

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, Trustee
Date:	04/06/2026

THE FEINBERG FAMILY FOUNDATION

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, Trustee
Date:	04/06/2026

ORACLE ASSOCIATES, LLC

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, Managing Member
Date:	04/06/2026

ORACLE INVESTMENT MANAGEMENT, INC.

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Larry N. Feinberg, President
Date:	04/06/2026

FEINBERG FAMILY TRUST

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Adam Usdan, Trustee
Date:	04/06/2026

ADAM USDAN

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Adam Usdan
Date:	04/06/2026

Adam H. Dublin

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Adam H. Dublin
Date:	04/06/2026

ADAM H. DUBLIN 2019 FAMILY TRUST

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Edward F. Spaniel, Jr., Co-Trustee
Date:	04/06/2026

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Phyllis Dublin
Date:	04/06/2026

Phyllis Dublin

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Phyllis Dublin
Date:	04/06/2026

Edward Francis Spaniel, Jr.

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Edward F. Spaniel, Jr.
Date:	04/06/2026

Peter Dublin

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Peter Dublin
Date:	04/06/2026

Carl Berg

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Carl Berg
Date:	04/06/2026

MARBLE LANE PARTNERS I, LLC

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for David Mehlman, Managing Member
Date:	04/06/2026

Michael Sawyer

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Michael Sawyer
Date:	04/06/2026

NELL AND JANE CAMERON 2006 TRUST

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Keri Cameron, Trustee
Date:	04/06/2026

Shahir Kassam-Adams

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Shahir Kassam Adams
Date:	04/06/2026

360 Ventures, LLC

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Shahir Kassam-Adams, General Manager
Date:	04/06/2026

Charles Mele

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Charles Mele
Date:	04/06/2026

Michael Glick

Signature:	/s/ Max C. Wygod
Name/Title:	Max C. Wygod / Attorney-in-fact for Michael Glick
Date:	04/06/2026

Milk Town Partners LLC

Signature:	/s/ Max C. Wygod
Name/Title:	Attorney-in-fact for Thomas J. Coleman
Date:	04/06/2026

Thomas J. Coleman Revocable Trust

Signature:	/s/ Max C. Wygod
Name/Title:	Attorney-in-fact for Thomas J. Coleman
Date:	04/06/2026

Source: View Original Filing on SEC EDGAR

FAQ

What transaction involving Forian (FORA) is described in this Schedule 13D/A amendment?

The amendment describes a planned acquisition of Forian Inc. by a consortium-led vehicle via tender offer and merger. After the offer, a special purpose merger subsidiary will merge into Forian, leaving Forian as a wholly owned subsidiary of the acquiring parent.

What are the key conditions to closing the Forian (FORA) tender offer and merger?

Completion requires that shares tendered plus those already owned by the buyer exceed 50% of outstanding shares. Other conditions include accuracy of specified Forian representations, material performance of covenants, no continuing Company Material Adverse Effect, non-termination of the merger agreement and no blocking governmental order.

Who is providing financing support for the Forian (FORA) acquisition?

A Wygod/Bushnell family trust, acting as Sponsor, has issued an equity commitment letter to provide up to $5.5 million of equity funding. These funds are available solely to consummate the transactions and cover defined closing payments under the merger agreement, subject to its conditions.

How many Forian (FORA) shares were outstanding for ownership calculations in this filing?

Ownership percentages in the filing are calculated using 31,208,751 Forian common shares outstanding as of March 25, 2026. This outstanding share count comes from Forian’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, referenced throughout the amendment.

What is the Forian (FORA) shareholder consortium and how many shares does it reference?

The consortium is a group of shareholders acting under a detailed agreement to pursue the acquisition. They may be deemed a “group” under Section 13(d), with 20,689,142 shares beneficially owned in the aggregate by consortium members, though individual reporting persons expressly disclaim group beneficial ownership beyond their own reported holdings.